VolitionRx (NYSE-A:VNRX) Limited announced the pricing of an underwritten public offering with expected gross proceeds of $16.5 million.
The epigenetics company plans to offer 13 million shares at $1.27 per share. Underwriters also have the option to purchase an additional 1.95 million shares, according to a statement.
Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, the company said, including potential strategic acquisitions.
VolitionRx (NYSE-A:VNRX) is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel